BURLINGTON, Mass., Aug. 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Karin Hehenberger, Executive Vice President and Chief Medical Officer, will moderate a panel on diabetes at the 8^th Annual Swedish-American Life Science Summit (SALSS) on Thursday, August 23, 2012.

Dr. Hehenberger is a recognized expert and has spent most of her career in diabetes research. She is currently leading and coordinating Coronado's research programs for TSO (Trichuris suis ova or CNDO-201), the company's biologic agent for the treatment of autoimmune diseases, in such therapeutic areas as inflammatory bowel disease, type-1 diabetes, multiple sclerosis, psoriasis and autism.

Dr. Hehenberger will lead a panel titled "Diabetes - The Healthcare Crisis", which will include executives and distinguished professors from Janssen Research & Development, Karolinska Intitutet, Novo Nordisk, and Brummer & Partners.

The SALSS 2012 is being held for the eighth consecutive year in Stockholm. The exclusive program includes panel discussions and presentations by leading scientists, corporate executives and investors in life sciences worldwide.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.

The Coronado Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13033

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.